Picture of Xenon Pharmaceuticals logo

XENE Xenon Pharmaceuticals Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Annual income statement for Xenon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue6.8332.218.49.430
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses49.664.597.4139214
Operating Profit-42.8-32.3-79-129-214
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes-41.6-29.1-78.9-125-183
Provision for Income Taxes
Net Income After Taxes-41.6-28.8-78.9-125-182
Net Income Before Extraordinary Items
Net Income-41.6-28.8-78.9-125-182
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-40-28-77.1-125-182
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1.54-0.792-1.77-2.06-2.73